Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 348 entries
View as:

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

Phase: N/A Priority: Normal
NCT ID: NCT00829829 Org: User:
Start: 02/28/09 End: 06/30/10 Due: 06/30/11

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT05685173 Org: User:
Start: 04/12/23 End: 05/16/29 Due: 05/16/30

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT01859988 Org: User:
Start: 05/31/13 End: 09/30/14 Due: 09/30/15

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Phase: N/A Priority: Normal
NCT ID: NCT04206553 Org: User:
Start: 10/28/20 End: 01/05/25 Due: 01/05/26

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03972657 Org: User:
Start: 08/12/19 End: 07/03/26 Due: 07/03/27

Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)

Phase: N/A Priority: Normal
NCT ID: NCT06631677 Org: User:
Start: - End: - Due: -

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06444178 Org: User:
Start: 09/30/24 End: 11/26/25 Due: 11/26/26

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06137482 Org: User:
Start: 12/06/23 End: 02/11/25 Due: 02/11/26

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04646005 Org: User:
Start: 06/28/21 End: 05/29/24 Due: 05/29/25

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Phase: N/A Priority: Normal
NCT ID: NCT00609544 Org: User:
Start: - End: - Due: -

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00320788 Org: User:
Start: 04/30/06 End: 08/31/08 Due: 08/31/09

Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01688960 Org: User:
Start: 10/31/12 End: 11/30/14 Due: 11/30/15

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT04126317 Org: User:
Start: 11/04/19 End: 11/30/21 Due: 11/30/22

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT03175367 Org: User:
Start: 11/10/17 End: 12/14/20 Due: 12/14/21

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03969004 Org: User:
Start: 06/04/19 End: 03/26/28 Due: 03/26/29

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Phase: N/A Priority: Normal
NCT ID: NCT06269133 Org: User:
Start: 02/21/24 End: 06/23/27 Due: 06/23/28

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Phase: N/A Priority: Normal
NCT ID: NCT00383370 Org: User:
Start: 10/31/06 End: 07/31/08 Due: 07/31/09

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04077099 Org: User:
Start: 01/07/20 End: 01/01/32 Due: 01/01/33

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

Phase: N/A Priority: Normal
NCT ID: NCT06602726 Org: User:
Start: 11/06/24 End: 08/18/25 Due: 08/18/26

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT01605708 Org: User:
Start: 06/30/12 End: 04/30/13 Due: 04/30/14

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05125016 Org: User:
Start: 11/30/21 End: 01/14/27 Due: 01/14/28

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02760498 Org: User:
Start: 04/07/16 End: 10/18/23 Due: 10/18/24

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03146416 Org: User:
Start: 05/16/17 End: 06/14/18 Due: 06/14/19

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Phase: N/A Priority: Normal
NCT ID: NCT04577820 Org: User:
Start: 10/13/21 End: 10/08/22 Due: 10/08/23

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02741739 Org: User:
Start: 03/31/16 End: 05/31/16 Due: 05/31/17